Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in >15 000 individuals

Simple item page
dc.contributor.authorAgarwal, Rajiv
dc.contributor.authorHauske, Sibylle Jenny
dc.contributor.authorWheeler, David C.
dc.contributor.authorDoi, Kent
dc.contributor.authorElsaesser, Amelie
dc.contributor.authorRitter, Ivana
dc.contributor.authorSteubl, Dominik
dc.contributor.authorWanner, Christoph
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2022-05-12T15:29:24Z
dc.date.available2022-05-12T15:29:24Z
dc.date.issued2022
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationAgarwal, R., Hauske, S. J., Wheeler, D. C., Doi, K., Elsaesser, A., Ritter, I., Steubl, D., & Wanner, C. (2022). Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in >15 000 individuals. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14694en_US
dc.identifier.issn1463-1326en_US
dc.identifier.urihttps://hdl.handle.net/1805/28964
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1111/dom.14694en_US
dc.relation.journalDiabetes, Obesity and Metabolismen_US
dc.rightsPublisher Policyen_US
dc.sourceAuthoren_US
dc.subjectacute kidney injuryen_US
dc.subjectSGLT2 inhibitoren_US
dc.subjectkidney diseaseen_US
dc.titleEmpagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in >15 000 individualsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Agarwal2022Empagliflozin-AAM.pdf
Size:
366.2 KB
Format:
Adobe Portable Document Format
Description:
Author's Manuscript
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Medicine Works